Two AstraZeneca (NYSE:AZN) cancer drugs received have orphan status for treatment of liver cancer by the FDA, a designation that may eventually speed progress to approval.
The special status was granted to Imfinzi, a lung cancer treatment, and tremelimumab, which has been tested in a combination in a variety of cancers.
Lynparza, another Astra drug, was also given FDA priority review for a severe form of prostate cancer, the company said separately.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.